Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation

Digestive Diseases and Sciences

Volumn 55, Issue 10, 2010, Pages 2912-2921

  Sloots, Cornelius E J ^b   Rykx, An ^a   Cools, Marina ^a   Kerstens, Rene ^a   De Pauw, Martine ^a  

^a Movetis   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISACODYL; OPIATE; PLACEBO; PRUCALOPRIDE; BENZOFURAN DERIVATIVE; LAXATIVE; NARCOTIC ANALGESIC AGENT; SEROTONIN AGONIST;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER PAIN; CHRONIC PAIN; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; INTESTINE FUNCTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; ELECTROCARDIOGRAPHY; MIDDLE AGED; MULTICENTER STUDY; PLACEBO EFFECT; TREATMENT OUTCOME; VITAL SIGN;

ABDOMINAL PAIN; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; BENZOFURANS; CONSTIPATION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LAXATIVES; MALE; MIDDLE AGED; PLACEBO EFFECT; SEROTONIN AGONISTS; TREATMENT OUTCOME; VITAL SIGNS; YOUNG ADULT;

EID: 77957924970     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1229-y     Document Type: Article

References (39)

1. IMS Health National Prescription Audit, 2006.
2. IMS Health MIDAS database, 2005.
3. Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61:1181-1187.
4. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity and impact of opioidinduced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10:35-42.
5. de Luca A, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Ther. 1996;69:103-115.
6. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil. 2004;16:17-28.
7. Holzer P. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs. 2007;16:181-194.
8. Mehendale SR, Yuan CS. Opioid-induced gastrointestinal dysfunction. Dig Dis. 2006;24:105-112.
9. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005;7:R1046-R1051.
10. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182:11S-18S.
11. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372-380.
12. Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ. 2001;322:1154-1158.
13. Adler HF, Atkinson AJ, Ivy AC. Effect of morphine and dilaudid on the ileum and of morphine, dilaudid and atropine on the colon of man. Arch Intern Med. 1942;69:974-985.
14. Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut. 1999;44:682-686.
15. De Schryver AM, Andriesse GI, Samsom M, Smout AJ, Gooszen HG, Akkermans LM. The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther. 2002;16:603-612.
16. de Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT (4) receptor agonists: Similar but not the same. Neurogastroenterol Motil. 2008;20:99-112.
17. Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil. 2001;13:465-472.
18. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001;120:354-360.
19. Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a doubleblind, placebo-controlled clinical trial. Digestion. 2003;67:82-89.
20. Emmanuel AV, Kamm MA, Roy AJ, Antonelli K. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut. 1998;42:511-516.
21. Emmanuel AV, Roy AJ, Nicholls TJ, Kamm M.A. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther. 2002;16:1347-1356.
22. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29:315-328.
23. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebocontrolled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344-2354.
24. Tack J, Van Outryve MV, Beyens G, Kerstens R, Vandeplassche L. Effect of prucalopride (RESOLOR) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58:357-365.
25. Van Outryve MV, Beyens G, Kerstens R, Vandeplassche L. Long-term follow up study of oral prucalopride (Resolar) administered to patients with chronic constipation. Gastroenterology. 2008;134:A-A547.
26. Mueller-Lissner SA, Rykx A, Kerstens R, Vandeplassche L. Randomized double-blind placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor) in elderly patients with chronic constipation. Gastroenterology. 2008;134:A-A157. [Abstract no 1052].
27. Frank L, Kleinman L, Farup C, Taylor L, Miner P Jr. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol. 1999;34:870-877.
28. Slappendel R, Simpson K, Dubois D, Keininger DL. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain. 2006;10:209-217.
29. Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol. 2005;40:540-551.
30. Johanson J, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25:599-608.
31. Voskuijl W, de Lorijn F, Verwijs W, et al. PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial. Gut. 2004;53:1590-1594.
32. Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7:39-46.
33. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13:56-64.
34. Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008;24:3503-3512.
35. Webster L, Jansen JP, Peppin J, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain. 2008; 137:428-440.
36. Sloots CE, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther. 2002;16: 759-767.
37. Camilleri M, Specht Gryp R, Kerstens R, Vanderplassche L. Efficacy of 12-week treatment with prucalopride (Resolor) in patients with chronic constipation: combined results of three identical randomized, double-blind, placebo controlled phase III trials. Gastroenterology. 2008;134:A-A548.
38. Tack J, Ausma J, Kerstens R, Vanderplassche L. Safety and tolerability of prucalopride (Resolor) in patients with chronic constipation: pooled data from three pivotal phase III studies. Gastroenterology. 2008;134:25-530.
39. Johnson D. Treating chronic constipation: how should we interpret the recommendations? Clin Drug Investig. 2006;26:547-557.